# An open-science consortium on the undruggable drivers, open until a candidate

Source: https://onco.cc/ideas/idea-fund-precompetitive-undruggable-consortium/  
OnCo record `idea-fund-precompetitive-undruggable-consortium` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Companies and public funders would pool money and scientists to crack the hardest cancer proteins, such as MYC and mutant p53, sharing everything openly until there is a real drug candidate, then competing on the final product.

## Summary

A consortium on the Structural Genomics Consortium and Open Targets model, but aimed at the highest-value undruggable oncology targets: MYC, mutant p53 reactivation, non-G12C RAS alleles beyond current inhibitors, fusion oncoproteins, transcription-factor and phosphatase targets. Members fund shared structural biology, chemical biology, degrader and molecular glue platforms and open probe generation, with an agreement that all results are published without patents up to the point of a validated chemical series, after which members may file and compete. The public benefit is a decade of duplicated, secret failure replaced by a shared map of what does and does not work.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: An open consortium of at least eight companies and three public funders produces open, potent chemical probes for at least three previously undrugged oncology target classes within six years and at least two members enter clinical development with compounds derived from consortium-enabled chemistry.
- Rationale: SGC has released hundreds of structures and dozens of open chemical probes that seeded later drug programmes (including in epigenetics), demonstrating that competitors will share pre-competitive science; KRAS G12C became druggable through academic chemistry that was widely published, after which competition produced multiple drugs quickly.
- Proposed test: Constitute the consortium with a three-target initial portfolio and publish annual progress including negative results; success at year four is at least one open probe with demonstrated cellular activity per target class.
- Maturity: early-clinical
- Actor: industry

## Sources

- Structural Genomics Consortium: https://www.thesgc.org/
- Open Targets: https://www.opentargets.org/

## Connected records

- ideas: [A pre-competitive consortium to validate or kill academic targets before licensing](https://onco.cc/ideas/idea-fund-target-validation-consortium/), [Milestone prizes for first-in-class mechanisms reaching human proof of concept](https://onco.cc/ideas/idea-fund-first-in-class-prize/)
- roadmaps: [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [KRAS](https://onco.cc/targets/kras/), [Menin](https://onco.cc/targets/menin/), [TP53](https://onco.cc/targets/tp53/)
- institutions: [Broad Institute of MIT and Harvard](https://onco.cc/institutions/broad-institute/), [The Francis Crick Institute](https://onco.cc/institutions/francis-crick/)
- pathways: [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- bottlenecks: [Secrecy and intellectual property block collaboration](https://onco.cc/bottlenecks/b-ip-collaboration/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-precompetitive-undruggable-consortium.json